Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN SIEGEL

NPI
1639110224
CMS profile
1288429
Location
MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,724.37

196 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,716.56 195
Education $7.81 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN SIEGEL

NPI 1639110224 · CMS profile ID 1288429

MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639110224?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN SIEGEL, NPI 1639110224, CMS profile ID 1288429. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639110224?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JONATHAN SIEGEL, NPI 1639110224, CMS profile ID 1288429. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639110224?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JONATHAN SIEGEL, NPI 1639110224, CMS profile ID 1288429, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1639110224?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

196 matching records · $2,724.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 196 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 196.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.9206/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959809439 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $29.7206/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960059145 CMS
Janssen Biotech, Inc. $16.4106/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885480427 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.2306/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955827615 CMS
ABBVIE INC. $19.6006/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602993 CMS
Daiichi Sankyo Inc. $24.7206/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930848121 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.3206/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959856250 CMS
ABBVIE INC. $10.6105/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602991 CMS
Janssen Biotech, Inc. $1.9805/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885480393 CMS
ABBVIE INC. $14.3305/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602989 CMS
ABBVIE INC. $15.2105/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602987 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.7605/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959640477 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.8305/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959813207 CMS
ABBVIE INC. $13.0205/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602985 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.3605/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955827611 CMS
ABBVIE INC. $12.9605/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602983 CMS
ABBVIE INC. $14.5005/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602981 CMS
Celgene Corporation $8.0505/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932685729 CMS
Braintree Laboratories, Inc. $17.9505/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898420961 CMS
ABBVIE INC. $15.9205/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602979 CMS
Takeda Pharmaceuticals U.S.A., Inc. $9.1605/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955827609 CMS
ABBVIE INC. $9.9204/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602977 CMS
Celgene Corporation $16.7804/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932685763 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.4104/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959404851 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.0904/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959955247 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.3004/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960049109 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.9804/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960049893 CMS
ABBVIE INC. $9.0904/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602975 CMS
Janssen Biotech, Inc. $16.2504/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885480411 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.6104/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959835449 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.5104/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959903847 CMS
ABBVIE INC. $22.8904/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602973 CMS
INTERCEPT PHARMACEUTICALS, INC. $16.2904/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951529603 CMS
ABBVIE INC. $49.9704/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602971 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.3804/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955827605 CMS
Celgene Corporation $10.3804/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932685727 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.2204/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959422327 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.6604/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959490127 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $2.5604/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959806799 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.9304/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959839795 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.4604/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959955883 CMS
FUJIFILM Healthcare Americas Corporation $14.8904/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950926387 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.7404/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959506631 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.4204/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959608021 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.9704/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959793243 CMS
ABBVIE INC. $26.6203/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602969 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.8903/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955827601 CMS
ABBVIE INC. $12.9303/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891602967 CMS
Celgene Corporation $19.1203/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932685761 CMS
Daiichi Sankyo Inc. $13.2203/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930809695 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,396.72 96
PY2020 $781.46 55
PY2021 $1,842.42 119
PY2022 $2,724.37 196
PY2023 $2,277.94 152
PY2024 $2,831.63 177
PY2025 $2,838.18 175

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $395,546.57 43
PY2024 Principal investigator $310,314.30 39
PY2023 Principal investigator $730,625.65 54
PY2022 Principal investigator $234,547.56 85
PY2021 Principal investigator $160,768.95 54
PY2020 Principal investigator $499,540.02 152
PY2019 Principal investigator $262,861.76 96

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $15,000.00 12/17/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211600210
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,500.00 12/17/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211600214
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,000.00 12/17/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211600222
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,500.00 12/17/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211600227
Principal investigator 1 ABBVIE INC. $2,500.00 12/11/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202530144
Principal investigator 1 ABBVIE INC. $1,560.35 12/11/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202530146
Principal investigator 1 ABBVIE INC. $731.53 12/04/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202528130
Principal investigator 1 ABBVIE INC. $260.35 12/02/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202526296
Principal investigator 1 ABBVIE INC. $11,340.00 11/26/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202525442
Principal investigator 1 ABBVIE INC. $15,041.71 10/09/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202515899
Principal investigator 1 ABBVIE INC. $33,210.00 09/16/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202511068
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,000.00 09/10/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223285177
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 09/10/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223285207
Principal investigator 1 ABBVIE INC. $1,213.25 09/03/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202508200
Principal investigator 1 PFIZER INC. $1,200.00 09/03/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228834869
Principal investigator 1 PFIZER INC. $1,836.00 09/03/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228834874
Principal investigator 1 PFIZER INC. $2,000.00 09/03/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228834878
Principal investigator 1 ABBVIE INC. $25.00 08/26/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202505945
Principal investigator 1 ABBVIE INC. $5,892.76 08/06/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202502663
Principal investigator 1 ABBVIE INC. $21,000.00 08/06/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202502665
Principal investigator 1 ABBVIE INC. $8,816.60 07/02/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202495171
Principal investigator 1 ABBVIE INC. $276.75 07/02/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202495173
Principal investigator 1 ABBVIE INC. $33,210.00 06/11/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202490887
Principal investigator 1 ABBVIE INC. $8,367.00 06/03/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202489055
Principal investigator 1 Genentech, Inc. $851.00 05/23/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211600244
Principal investigator 1 PFIZER INC. $813.00 05/23/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228849396
Principal investigator 1 PFIZER INC. $1,013.00 05/23/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850037
Principal investigator 1 PFIZER INC. $750.00 05/23/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850314
Principal investigator 1 PFIZER INC. $300.00 05/23/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850398
Principal investigator 1 PFIZER INC. $14,812.00 05/23/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850405
Principal investigator 1 ABBVIE INC. $8,584.20 05/07/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202482675
Principal investigator 1 Genentech, Inc. $130,203.00 04/23/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211600247
Principal investigator 1 PFIZER INC. $1,457.00 04/11/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850142
Principal investigator 1 ABBVIE INC. $4,774.48 04/03/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202471676
Principal investigator 1 PFIZER INC. $801.00 03/17/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854110
Principal investigator 1 PFIZER INC. $1,775.00 03/17/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854117
Principal investigator 1 ABBVIE INC. $1,213.25 03/06/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202458043
Principal investigator 1 Genentech, Inc. $2,684.00 02/26/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211600235
Principal investigator 1 Genentech, Inc. $2,020.00 02/19/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211600240
Principal investigator 1 PFIZER INC. $3,357.00 02/03/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854085
Principal investigator 1 ABBVIE INC. $6,456.94 01/21/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD) No dispute reported 06/30/2026 1202440459
Principal investigator 1 Genentech, Inc. $27,232.00 01/13/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211600231
Principal investigator 1 ABBVIE INC. $1,468.40 01/02/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202434099